Thermo Fisher Scientific's (TMO) Dividend: Steady Payouts in a Growing Market

Thermo Fisher Scientific Inc. (NYSE:TMO) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025.

The stock is down by over 21% since the start of 2025; however, it continues to be a strong long-term growth company, supported by its large scale, diverse operations, and steady high-margin recurring revenue streams, which make up 83% of its total sales. At its foundation, the company is a leading supplier of instruments, diagnostics, bioproduction tools, and outsourced clinical and manufacturing services.

In the first quarter of 2025, Thermo Fisher Scientific Inc. (NYSE:TMO) reported revenue of $10.36 billion, up nearly 1% from the same period last year. The revenue also beat analysts’ estimates by $130 million. The company relied on the PPI Business System to enhance operational efficiency and support its customers’ success. It also made progress on its established growth strategy by rolling out several impactful and innovative products during the quarter.

Thermo Fisher Scientific Inc. (NYSE:TMO) is a solid dividend payer with a robust cash position. In the most recent quarter, the company generated an operating cash flow of $723 million, and its free cash flow was $373 million. In February, it raised its dividend for the eighth consecutive year. It offers a quarterly dividend of $0.43 per share and has a dividend yield of 0.42%, as recorded on July 17.

While we acknowledge the potential of TMO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 13 Best Industrial Dividend Stocks to Buy Right Now and 10 Best Passive Income Stocks to Buy Now.

Disclosure: None.